Navigation Links
IDM Pharma Reports Third Quarter 2007 Financial Results
Date:11/8/2007

sed by sanofi-aventis.

Research and development expenses were $6.4 million and $5.3 million for the three months ended September 30, 2007 and September 30, 2006, respectively. The increase during the 2007 period was primarily due to an increase in spending of $2.1 million related to clinical development, regulatory filings and manufacturing of L-MTP-PE, and clinical development of UVIDEM. The increase was partially offset by a $0.4 million reduction in spending associated with development activities related to products currently on hold, as well as a $0.8 million reduction associated with lower headcount and termination of a lease agreement for certain of the Company's Paris facilities.

Selling, general and administrative expenses were $2.7 million and $1.8 million for the three months ended September 30, 2007 and 2006, respectively. The increase of $0.9 million in 2007 included $0.3 million of bonus accruals, $0.2 million of stock compensation expense and $0.2 million of consulting and salary expense.

Net interest income was $3.1 million for the three months ended September 30, 2007, as compared to net interest income of $0.1 million for the three months ended September 30, 2006. During the quarter ended September 30, 2007, the Company recognized $0.4 million of interest income associated with its investments and a $2.7 million reduction in non-cash interest expense for the net decrease in the fair value of warrants issued in connection with the February and June 2007 financings.

The foreign exchange loss was $0.8 million in the third quarter of 2007, compared to a foreign exchange gain of $0.2 million in the third quarter of 2006. The increase in 2007 was due to higher spreads between the value of the U.S. dollar and the Euro compared to the prior year as the dollar denominated inter-company loan between the Company's subsidiaries is revalued each quarter based on changes in the value of the dollar versus the Euro, with all related changes
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Thousands ... to move forward in a number of multidistrict litigations ... West Virginia, Bernstein Liebhard LLP reports. According to an ... scheduled to convene a Joint Status Conference in all ... a.m. Parties have been directed to submit a proposed ...
(Date:12/25/2014)... 2014 Residents at Abernethy ... showed their generous spirit by providing holiday gifts ... Parenting Network- Grandparents Raising Grandchildren program. , Following ... the largest Christmas tree on the campus of ... residents of the Abernethy Village Association (AVA). Each ...
(Date:12/24/2014)... 2014 AlignLife of Wauwatosa loves ... certain items. During the holiday season, AlignLife looks forward to ... toys," says Dr. Sara Mahalko-Leonhardt, owner of AlignLife. "It brings ... knowing that we are able to give kids toys for ... been for the generosity of our patients." , The 70 ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... The Malaria in Pregnancy Consortium, led by the Liverpool ... by the European and Developing Countries Clinical Trials Partnership ... of an antimalarial drug given to prevent malaria in ... a major cause of severe maternal anaemia and preventable ...
... down Silos and Benefiting from Paperless Lab MILFORD, ... Corporation (NYSE: WAT ) and LabVantage ... to integrate laboratory software for improved efficiency and ... existing common customers, Waters(R) and LabVantage(R) have already ...
... A new analysis by Avalere Health found that ... -- a full 10% higher than amounts reported in ... not include spending on assisted living, a key component ... California-based SCAN Foundation, found that individuals and their families ...
... Leader BioFortis wins another award for its ... and institutional clients worldwide for translational research, ... March 5 /PRNewswire/ -- BioFortis, ... solutions used by pharmaceutical and institutional clients, ...
... the Basics: Healthy Living Web Source Offers Tips on Fitness ... & Spa ExperienceWESTCHESTER, Ill., March 5 Research shows that ... fall off the wagon by Valentine,s Day(1). If this ... in the first place? Old London, the makers of ...
... Philadelphia, 5 March 2009 The new medical subspecialty ... the way in providing technically advanced yet cost-effective care ... in the March issue of the Journal of ... the Heart Failure Society of America (HFSA) and the ...
Cached Medicine News:Health News:LSTM and MiP Consortium awarded further $4.5 million 2Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 2Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 3Health News:Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work 4Health News:Almost 30% of Long-Term Care is Financed Out-of-Pocket, Report Finds 2Health News:BioFortis Wins Best Product Award in Discovery Informatics at the 2009 Molecular Medicine Tri-Conference 2Health News:Samantha Harris Launches 'A Toast for Everyday Health' 2Health News:Samantha Harris Launches 'A Toast for Everyday Health' 3Health News:Samantha Harris Launches 'A Toast for Everyday Health' 4Health News:New specialty to focus on advanced heart failure and heart transplantation 2
(Date:12/22/2014)... 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical care ... technology to help fight deadly inflammation in critically-ill ... today announced the appointment of Dr. Gregory ... Senior Vice President of Clinical Development, effective January ... Russo is an accomplished pediatric cardiothoracic surgeon ...
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... Jan. 17, 2012 To address the growing need ... with the automation of routine clinical laboratory assays, ... Tecan Group (SIX Swiss Exchange: TECN) today entered into ... handling platform with Waters® ACQUITY® TQD liquid ...
... RIVER EDGE, N.J., Jan. 17, 2012  Nephros, Inc. (OTC ... developing and marketing filtration products for therapeutic applications, infection ... 16, 2012, Nephros received a payment of euro 750,000 ... Under the terms of the license agreement ...
Cached Medicine Technology:Waters and Tecan Sign Agreement for Clinical Assay Platform 2Waters and Tecan Sign Agreement for Clinical Assay Platform 3Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 2Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 3Nephros Receives Euro 750,000 Payment from Bellco S.r.l. 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: